GEN Exclusives

More »

GEN News Highlights

More »
Jul 15, 2013

EU OKs Roche’s Erivedge for Treating Advanced Basal Cell Carcinoma

  • Roche today said its Erivedge (vismodegib) has won conditional approval from the European Commission for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. This approval makes Roche’s drug the first licensed medicine for BCC patients in the EU.

    Erivedge—a hedgehog pathway inhibitor—earned FDA approval for treatment of patients with advanced BCC in January 2012. Since October 2012, it has also been approved in Switzerland, Australia, Israel, South Korea, Mexico and Ecuador, according to Roche. 

    “Today’s approval is great news for patients with advanced basal cell carcinoma, who previously had no medicines to treat their disease,” Roche’s Hal Barron, M.D., CMO and head, global product development, said in a statement. “Erivedge substantially reduced tumor size in patients in clinical trials, and we are pleased that Erivedge will now be available to patients in the European Union.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?